Associations of plasma fibrinogen and factor VII clotting activity with coronary heart disease and stroke: Prospective cohort study from the screening phase of the Thrombosis Prevention Trial

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 11, 2006, Pages 2405-2410

  Rudnicka, Alicia R ^a   Mt Isa, S ^b   Meade, T W ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Coronary heart disease; Factor VIIc; Fibrinogen; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 7; FIBRINOGEN;

ADULT; AGE; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; CORRELATION ANALYSIS; FATALITY; FIBRINOGEN BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MORTALITY; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK ASSESSMENT; STROKE; THROMBOSIS;

AGE FACTORS; AGED; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; FACTOR VII; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; THROMBOSIS;

EID: 33750076962     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02221.x     Document Type: Article

References (38)

1. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA 2005; 294: 1799-809.
2. Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351: 233-41.
3. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
4. Heinrich J, Balleisen L, Schulte H, Assmann G, van de LJ. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-9.
5. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-8.
6. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
7. Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: Results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 1999; 19: 1776-83.
8. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, Barzegar S, Mitchell JP, Rosenberg RD. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102: 2816-22.
9. Smith A, Patterson C, Yarnell J, Rumley A, Ben Shlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005; 112: 3080-7.
10. von Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 17: 237-46.
11. Brozovic M, Stirling Y, Harricks C, North WR, Meade TW. Factor VII in an industrial population. Br J Haematol 1974; 28: 381-91.
12. Armstrong BG. The effects of measurement errors on relative risk regressions. Am J Epidemiol 1990; 132: 1176-84.
13. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am J Epidemiol 1992; 136: 1400-13.
14. Easton DF, Peto J, Babiker AG. Floating absolute risk: An alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med 1991; 10: 1025-35.
15. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
16. Youngman LD, Keavney BD, Palmer A, Parish S, Clark S, Danesh J, Delepine M, Lathrop M, Peto R, Collins R. Plasma fibrinogen and fibrinogen genotypes in 4685 cases of myocardial infarction and in 6002 controls: test of causality by 'Mendelian randomisation'. Circulation 2000; 102 (Suppl. II): 31-2.
17. Davey Smith G, Harbord R, Milton J, Ebrahim S, Sterne JA. Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies. Arterioscler Thromb Vasc Biol 2005; 25: 2228-33.
18. Davey Smith G, Ebrahim S. 'Mendelian randomization': Can genetic epidemiology contribute to understanding environmental determinants of disease ? Int J Epidemiol 2003; 32: 1-22.
19. Palmer LJ, Cardon LR. Shaking the tree: Mapping complex disease genes with linkage disequilibrium. Lancet 2005; 366: 1223-34.
20. Meade TW, Humphries SE, De Stavola B. Commentary: Fibrinogen and coronary heart disease - test of causality by 'Mendelian'randomization'by Keavney et al. Int J Epidemiol 2006; 35: 944-7.
21. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: Complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-31.
22. Davey Smith G, Harbord R, Ebrahim S. Fibrinogen, C-reactive protein and coronary heart disease: Does Mendelian randomization suggest the associations are non-causal ? QJM 2004; 97: 163-6.
23. Meade TW. Fibrinogen measurement to assess the risk of arterial thrombosis in individual patients: Yes. J Thromb Haemost 2005; 3: 632-4.
24. Lowe GD. Blood viscosity and cardiovascular disease. Thromb Haemost 1992; 67: 494-8.
25. Meade TW, Vickers MV, Thompson SG, Stirling Y, Haines AP, Miller GJ. Epidemiological characteristics of platelet aggregability. Br Med J (Clin Res Ed) 1985; 290: 428-32.
26. Lowe GD, Reavey MM, Johnston RV, Forbes CD, Prentice CR. Increased platelet aggregates in vascular and nonvascular illness: Correlation with plasma fibrinogen and effect of ancrod. Thromb Res 1979; 14: 377-86.
27. Gurewich V, Lipinski B, Hyde E. The effect of the fibrinogen concentration and the leukocyte count on intravascular fibrin deposition from soluble fibrin monomer complexes. Thromb Haemost 1976; 36: 605-14.
28. Scrutton MC, Ross-Murphy SB, Bennett GM, Stirling Y, Meade TW. Changes in clot deformability -a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction. Blood Coagul Fibrinolysis 1994; 5: 719-23.
29. Smith EB. Haemostatic factors and atherogenesis. Atherosclerosis 1996; 124: 137-43.
30. Smith EB, Keen GA, Grant A, Stirk C. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10: 263-75.
31. MacCallum PK, Cooper JA, Rumley A, Lowe GD, Meade TW. Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease. J Thromb Haemost 2004; 2: 364-5.
32. Assmann G, Cullen P, Heinrich J, Schulte H. Hemostatic variables in the prediction of coronary risk: Results of the 8year follow-up of healthy men in the Munster Heart Study (PROCAM). Prospective Cardiovascular Munster Study. Isr J Med Sci 1996; 32: 364-70.
33. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-8.
34. Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: Comparing contributions from primary prevention and secondary prevention. BMJ 2005; 331: 614.
35. Wright JD, Kennedy-Stephenson J, Wang CY, McDowel. MA, Johnson CL. Trends in intake of energy and macronutrients -United States 1971-2000. JAMA 2004; 291: 1193-4.
36. Miller GJ, Martin JC, Webster J, Wilkes H, Miller NE, Wilkinson WH, Meade TW. Association between dietary fat intake and plasma factor VII coagulant activity - a predictor of cardiovascular mortality. Atherosclerosis 1986; 60: 269-77.
37. Ergin A, Muntner P, Sherwin R, He J. Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States. Am J Med 2004; 117: 219-27.
38. Laatikainen T, Critchley J, Vartiainen E, Salomaa V, Ketonen M, Capewell S. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol 2005; 162: 764-73.